Partway Share Discussion Threads

[rafboy] 06/12/2019 15:49

NO PROFIT WARNING COMING IMHO

[onjohn] 05/12/2019 15:08

PROFIT WARNING COMING IMHO

[flashheart] 05/12/2019 14:05

Apologies Parity holders as my post probably more at home on the Integumen board.

[flashheart] 05/12/2019 14:04

I've already been contemplating that Katsy as well. Not beyond the realms of possibility although a major transaction. Imagine the company in the making in the result though eh......mind boggling. Whatever the result and the reason behind the recent share price weakness (for no apparent reason as yet) I'm confident GB has all avenues covered and is building a beast to be reckoned with.

[katsy] 05/12/2019 13:56

Could this be a target for Integumen if indeed they are raising funds for an acquisition? c£10m Mcap with multople of that in revenue. If GB could cut cost and streamline the business like he's done for Integumen it could be a very profitable business. It would mean a massive dilution for SKIN shareholders though.

[my retirement fund] 04/12/2019 06:46

Well a few token shares purchased by director and its market cap went up bu a third. Really. REALLY !!!

[insideryou] 19/11/2019 09:54

Agree. It's looking cheap with huge potential.

[mulligut] 19/11/2019 08:10

Great if it would do the same rerating that SKIN had with data and be a multibagger

[parsons4] 19/11/2019 07:31

I am an investor in SKIN but am watching here with interest. Low market cap, high turnover and a new management team all point to a possible multi-bagger even after a 50% rise.

[thorne3] 15/11/2019 16:10

ONJohnIs it not about time that you kept it shut?

[fillipe] 15/11/2019 13:24

Asking 9.5p now an that almost being paid.

f

[rafboy] 15/11/2019 10:59

Indeed, that deal could well prove very good for both companies.

[mulligut] 15/11/2019 10:39

Yes and the price is moving up with the recent deal announcement of Integumen too

[rafboy] 15/11/2019 10:38

Nice to see interest growing here with a few buys this morning.

[onjohn] 13/11/2019 10:10

Todays news


One sad sack doing a deal with an equally sad sack

[soultrading] 13/11/2019 09:29

I bought shares here off the back of the SKIN partnership. I expect both companies to do well out of this deal.

[insideryou] 13/11/2019 07:58

Parity Group PLC HoT regarding revenue share on AI data platformSource: UK Regulatory (RNS & others)TIDMPTYRNS Number : 1793TParity Group PLC13 November 201913 November 2019AIM: PTYParity Group PLC("Parity" or "Company")Parity shares revenue with Integumen plc to deliver AI data platform solutions to clientsParity announces that it has signed Heads of Terms with Integumen plc to enter a multi-year Framework Agreement ("Agreement") to be completed on or before the 18th of December 2019. It is envisaged that the Agreement will give Parity access to Integumen's Artificial Intelligent ("AI") software which it can supply across its client base which includes the National Health Service ("NHS"), Central Government and Private Institutional clients.This Agreement accelerates Parity's transformation from a predominately commoditised recruitment business to a data consultancy service provider of intelligent data management systems, extracting value using analytics, with a focus on return on investment for our Company's 100+ institutional clients. The software includes full GDPR compliance with secure cloud data migration from existing legacy systems to a digital workplace through the military grade encryption "Drive4Growth" AI platform powered by Integumen's Rinodrive.Combined benefits:-- Recurring shared revenue streams for both Parity and Integumen in 2020 -- Value-added proposition in demand from Parity clients with c. 3 to 5-year annual contracts -- Immediate access to 100+ public and private institutional clients -- Trusted approved vendor for Government and private sectors for over 45 years -- 700+ data experts and 50+ enterprise sales and office professionals -- Existing cross-over access to educational institutional research facilities -- Access to multiple industry, public and private sector distribution routes to market -- Well defined roadmap to next level business growth for both Parity and Integumen Since the appointment of the new CEO, in February 2019, there has been structural changes to the business. Client management focus is on increasing profitability. New senior management has reduced high-volume low-margin business to low-volume high-margin multi-line business development. This includes new, higher value data expert professional service offerings. Reduction in headcount of 35% has resulted in a rolling 12-month gross cost saving of GBP2m. Heading into 2020 with these changes and with today's agreement, the board expect the Company will deliver a right-sized company with higher margins, increased profitability leading to improved shareholder value.Matthew Bayfield, CEO of Parity Group plc, comments:"Parity is pleased to be partnering with Integumen and rolling out the Drive4Growth AI platform to our client base. We have been working with many of the same clients for 45 years, so we understand their needs. With healthcare sector data in 2020 expected to double every 73 days, our clients need to securely manage and extract greater value using analytics and AI in order to make important decisions. The Drive4Growth AI platform delivers on those requirements, increases revenue per client, increases client contract term and generates a higher margin, leading to greater profitability."Gerard Brandon, CEO of Integumen plc, comments:"We are delighted to be able to roll-out the Drive4Growth AI platform in partnership with the credibility and reputation that Parity data experts hold with an extensive list of public and private institutions. We look forward to working alongside Parity to extract greater value for their clients and contribute to the transformation of the UK's National Health Service, public and private institution data over the next few years."Certain information contained in this announcement would have constituted inside information (as defined by Article 7 of Regulation (EU) No 596/2014) ("MAR") prior to its release as part of this announcement and is disclosed in accordance with the Company's obligations under Article 17 of MAR.ContactsMatthew Bayfield, CEO [phone] Parity Group plc Roger Antony, GFD 5353 WH Ireland Limited Mike Coe [phone] (Nominated Adviser & Broker) Chris Savidge 3470 -------------------- ----------------- [phone] Donhead Consultants (Broker) David Beck 383 -------------------- ----------------- About Parity Group: www.parity.netParity helps organisations find the right people, skills and data to support data-led business decisions. Providing advice on data and with access to qualified personnel with skills offered, either as a managed service, through resourcing in the contract or permanent market or as part of a learning and development programme.Income derives from a mix of long-term contracts with public and private sector organisations as well as expanded projects with existing clients as a result of strong relationships and a track record of high client satisfaction. Key highlights comprising of:-- Over 45 years of expertise in public and private recruitment and service contract sector -- More than 50 employees across the UK -- Client numbers exceed 100 in both UK and Ireland -- Associate numbers supporting client services exceeds 700 About Integumen: www.integumen.comIntegumen is a vertically integrated product and services company for skin related diseases, treatments and therapies with four business units:-- Labskin AI's technology platform incorporates artificial intelligence within clinical research for medical device, pharmaceuticals, cosmeceuticals and related life science test services. Labskin allows skincare, healthcare, pharmaceutical manufacturers and cosmetic companies to test their products on human-like skin in a real-world environment with full access to multiple state-of-the-art partner technologies.-- Rinodrive is a data aggregation, refining and AI analysis open-source eco-system designed to provide third-party service providers the ability to offer their clients valuable insights that support clinical, operational and financial decisions in healthcare services, third-level education, government departments and the financial sector.-- Wound pHase is developing skin and wound care products using its proprietary wound dressing technology. Working in collaboration with CBD providers creating a CBD infused diabetic wound care product range.-- Stoer-for-men skin products e-commerce division offers a range of skincare products derived from 5 natural super-ingredient plant extracts specifically for men to reduce the signs of ageing and is also used as a control for client testing within Labskin laboratories.RinoDrive "Drive4Growth": www.rinodrive.comA fully integrated set of software tools that can ingest data, in any volume, from any source in any format, interact with it, learn from it and enrich it to unlock insights and discoveries.This data management solution was developed by scientists and engineers with experience in software, sensors, AI, optofluidic research, fintech, green-tech, travel and healthcare.It was designed to allow interaction, in a cyber-secure environment, with commercially sensitive data, and to share insights across multi-disciplinary teams, generating different data formats, from multiple sources, located in different countries.RinoDrive delivers big data, AI functionality and world class infrastructure to large companies with big data problems. These include financial services, education and life science companies. Most recently completing the automation of laboratories and application of AI to unearth more knowledge about the skin microbiome. This led to the acquisition in May 2019 by Integumen PLC, to secure access to, and the exploitation of data from some of the largest cosmetic, pharmaceutical and medical companies in the world.This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.ENDAGRFFIFWEFUSEFF(END) Dow Jones NewswiresNovember 13, 2019 02:00 ET (07:00 GMT)

[tiswas] 20/9/2019 12:50

Interesting first post cricket!

[cricketcrazy] 20/9/2019 12:28

This is an amazing achievement from a new CEO who in just 4 months has taken out over £1m of net costs, reorganised and refocused the business and made key new hires. With existing retained revenues of circa £44.5m, even if full year revenue allowing for the loss of the Scottish contract already announced,was only £70m the potential profits on margin improvement to just 5% would make the present market cap of the company look ridiculous. An exciting turnaround with big upside potential.

[onjohn] 20/9/2019 10:08

This is worthless o there is no IP.

profit warning ans 3p beckoneth

[weatherman] 20/9/2019 10:03

Pty has had many dawns, but it may be a long and difficult task. But what choice is there? Everything that is good or even middling, is getting taken out - Scysis, Statpro, Lombard, Stadium etc.

[garth] 20/9/2019 09:47

Well, a loss, but cashflow positive (£0.2M) and debt paid down to just over £1m. Cash outflow of £0.4M related to restructuring implies that they could eradicate that debt with free cashflow in a year?

Would you concur weatherman?

New broom got things finally set for a recovery that has been waiting twenty years to happen? Or is that too optimistic?

Back on the watch list after a few years of being dead dog (with fleas) in the kennel.

G.

[weatherman] 20/9/2019 08:40

That was not as bad as it could have been - with a positive change of direction towards a higher margin business.

[tiswas] 20/9/2019 08:39

You have to believe in the turnaround to continue holding these, nothing much in the historic results that encourages. If anyone sees any broker comment I would appreciate a summary.

[teamaccounting] 22/8/2019 09:12

Just tried to buy some, no volume offered, seems all booger’s are bidding for volume.
Two largest shareholders, Helium and Tim Watts have increased their shareholding recently !